#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Geriatrics and Gerontology / 2023 - 3

The day after: Atrial fibrillation and COVID-19

Czech version

Authors: Dúbrava Martin 1;  Jánošiová Jarmila 1;  Koščálová Alena 2;  Šuba Ján 1
Authors‘ workplace: I. klinika geriatrie LF UK a UN, Bratislava 1;  Klinika infektológie a geografickej medicíny UNB, LF UK a SZU Bratislava 2
Published in: Geriatrie a Gerontologie 2023, 12, č. 3: 135-140
Category:

Overview

Dúbrava M, Jánošiová J, Koščálová A, Šuba J. The day after: Atrial fibrillation and COVID-19

The COVID-19 pandemic has had the most devastating impact on seniors. This was also due to comorbidities and immunosenscence, which are so typical for older age. One of the characteristic diseases of seniors is atrial fibrillation (AF), which has a high potential to impair the quality of life and life expectancy. But at the same time, it is well treatable. The AF rate in seniors with COVID-19 is high, including first-diagnosed AF. The pathophysiology of AF developed during SARS-CoV-2 infection is complex. AF worsens the prognosis of patients with COVID-19. We are sure that we cannot pretend that the COVID-19 catastrophe has passed, that we are „the day after“ and can only focus ourselves on repairing the damage that has already occurred. Unfortunately, the opposite is true, SARS-CoV-2 has stayed with us and is mutating intensely. In this article, we offer one of the possible insights into current knowledge about the relationship between AF and COVID-19, with an emphasis on why the importance of AF screening in seniors increases significantly in the “postcovid” period. This screening can be implemented in several ways, some of which are feasible quickly and at minimal cost.

Keywords:

atrial fibrillation – COVID-19 – geriatrics

Sources
  1. Dúbrava M. Prečo dnes na Slovensku excesívne zomierame na SARS-CoV-2? Cardiology Lett 2021; 30(1): 10–13.
  2. Dúbrava M, Bořucký J, Koromházová A, et al. Profil nevakcinovaných seniorov s COVID-19 hospitalizovaných v tretej vlne pandémie. Geri a Gero 2022; 11(3): 109–117. 
  3. Chovancová Z. Imunosenescence – západ slunce nad imunitním systémem. Vnitř Lék 2020; 66(6): 353–358. 
  4. Sterling P, Eyer J. Allostasis: A new paradigm to explain arousal pathology. In: Fisher S, Reason J (eds.). Handbook of life stress, cognition and health. New York: John Wiley & Sons,1988: 629–649.
  5. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42(5): 373–498. 
  6. Dúbrava M, Jánošiová J, Koščálová A, et al. Gerontokardiológia: COVID-19. Cardiology Lett 2020; 29(5–6): 293–302.
  7. Manolis AS, Manolis AA, Manolis TA, et al. COVID-19 infection and cardiac arrhythmias. Trends Cardiovasc Med 2020; 30(8): 451–460. 
  8. Donniacuo M, De Angelis A, Rafaniello C, et al. COVID-19 and atrial fibrillation: Intercepting lines. Front Cardiovasc Med 2023; 10: 1093053. 
  9. Wang L, Hoang L, Aten K, et al. Mortality and major adverse cardiovascular events in hospitalized patients with atrial fibrillation with COVID-19. Am J Cardiol 2023; 189: 41–48. 
  10. Mountantonakis SE, Saleh M, Fishbein J, et al. Atrial fibrillation is an independent predictor for in-hospital mortality in patients admitted with SARS-CoV-2 infection. Heart Rhythm 2021; 18(4): 501–507.
  11. Fumagalli S, Trevisan C, Del Signore S, et al. Atrial fibrillation and COVID-19 in older patients: how disability contributes to shape the risk profile. An analysis of the GeroCovid registry. Aging Clin Exp Res 2022; 34(1): 249–256. 
  12. Rosenblatt AG, Ayers CR, Rao A, et al. New-onset atrial fibrillation in patients hospitalized with COVID-19: Results from the American Heart Association COVID-19 Cardiovascular Registry. Circ Arrhythm Electrophysiol 2022; 15(5): e010666. 
  13. Lip GYH, Genaidy A, Tran G, et al. Incident atrial fibrillation and its risk prediction in patients developing COVID-19: A machine learning based algorithm approach. Eur J Intern Med 2021; 91: 53–58. 
  14. Mónica RS, Maribel QF, Javier J, et al. Cardiac complications in a geriatric population hospitalized with COVID-19: The OCTA-COVID cohort. Rev Esp Geriatr Gerontol 2022; 57(2): 63–70.
  15. Mele M, Tricarico L, Centola A, et al. Impact of vaccination on electrocardiograms of hospitalized patients for Covid-19. Vaccine X 2023; 14: 100291. 
  16. Wang W, Wang CY, Wang SI, et al. Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: A retrospective cohort study from the TriNetX US collaborative networks. E Clinical Medicine 2022; 53: 101619. 
  17. Dúbrava M. Možnosti hodnotenia polymorbidity. Geriatria 2008; 14(2): 58–67. 
  18. Junior AF, Azevedo E, Paes AT, et al. Chronic diseases, chest computed tomography, and laboratory tests as predictors of severe respiratory failure and death in elderly Brazilian patients hospitalized with COVID-19: a prospective cohort study. BMC Geriatr 2022; 22(1): 132. 
  19. Woosley R. Risk categories for drugs that prolong QT & induce torsades de pointes (TdP) Arizona: AZCERT Arizona Center for Education and Research on Therapeutics. https://www.crediblemeds.org/druglist.
  20. Michaud V, Dow P, Al Rihani SB, et al. Risk assessment of drug-induced long QT syndrome for some COVID-19 repurposed drugs. Clin Transl Sci 2021; 14(1): 20–28. 
  21. Rossi R, Coppi F, Talarico M, et al. Protective role of chronic treatment with direct oral anticoagulants in elderly patients affected by interstitial pneumonia in COVID-19 era. Eur J Intern Med 2020; 77: 158–160. 
  22. Tomaszuk-Kazberuk A, Koziński M, Domienik-Karłowicz J, et al. Pharmacotherapy of atrial fibrillation in COVID-19 patients. Cardiol J 2021; 28(5): 758–766. 
  23. Bell M, Ekbom A, Linder M. COVID-19 and comedications in atrial fibrillation-a case-control study in Stockholm. Eur J Epidemiol 2023; 1–11. 
  24. Denas G, Gennaro N, Ferroni E, et al. Reduction in all-cause mortality in COVID-19 patients on chronic oral anticoagulation: A population-based propensity score matched study. Int J Cardiol 2021; 329: 266–269. 
  25. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA 2020; 323(16): 1574–1581. 
  26. Hernandez I, He M, Guo J, Tadrous M, et al. COVID-19 pandemic and trends in new diagnosis of atrial fibrillation: A nationwide analysis of claims data. PLoS One 2023; 18(2): e0281068. 
  27. Holt A, Gislason GH, Schou M, et al. New-onset atrial fibrillation: incidence, characteristics, and related events following a national COVID-19 lockdown of 5.6 million people. Eur Heart J 2020; 41(32): 3072–3079. 
  28. Attia ZI, Noseworthy PA, Lopez-Jimenez F, et al. An artificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: a retrospective analysis of outcome prediction. Lancet 2019; 394(10201): 861–867. 
  29. Lowres N, Neubeck L, Redfern J, Freedman SB. Screening to identify unknown atrial fibrillation. A systematic review. Thromb Haemost 2013; 110(2): 213–222.
  30. Svennberg E, Friberg L, Frykman V, et al. Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP): a multicentre, parallel group, unmasked, randomised controlled trial. Lancet 2021; 398(10310): 1498–1506. 
  31. Singer DE, Atlas SJ, Go AS, et al. ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals (GUARD-AF): Rationale and design of the GUARD-AF randomized trial of screening for atrial fibrillation with a 14-day patch-based continuous ECG monitor. Am Heart J 2022; 249: 76–85. 
  32. Dúbrava M, Németh F, Drobná T, et al. Fibrilácia predsiení u seniorov: základné dáta zo štúdie SAFIS (metodika, prevalencia a typy fibrilácie predsiení). Geriatria 2016; 22(1): 8–19. 
  33. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31(19): 2369–2429. 
  34. Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006; 27(8): 949–953. 
Labels
Geriatrics General practitioner for adults Orthopaedic prosthetics
Editorial
Preoperative examination of the elderly in primary care. Joint recommended practice of the Society of General Medicine and the Czech Gerontological and Geriatric Society ČLS JEP
Recommended tools for medication review and prescription optimization in geriatric patients
Anticoagulant treatment in patients with atrial fibrillation and chronic kidney disease – a common problem in the elderly
Transthyretin amyloidosis of the heart – a diagnosis to keep in mind even in old age
Should the doctor give in to the family’s insistence and give false information? (case study from practice)
28th National Gerontological Congress in Hradec Králové Fragile geriatric patient across disciplines – focus on surgery and oncology (pre- and post-operative care)
Article was published in

Geriatrics and Gerontology

Issue 3
2023 Issue 3
Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#